ANTI-CANCER DRUGS COMPRISING PLATINUM COMPLEXES

Abstract: There are provided anti-tumor agents comprising as active ingredient platinum complexed directly or via dextran­ amine moieties to an anti-tumor immunoglobulin. These are prepared by reacting an anti-tumor immunoglobulin or such immunoglobulin coupled to a dextran-amine with a platinum salt. Immunoglobulins having a specific binding activity towards certain types of cancer cells can be used. Immuno­ globulins specific for ovarian or testicular carcinoma or for renal adenocarcinoma complexed directly or via dextran­ amine moieties with platinum are effective agents for the treatment of these malignancies.

Description: ANTI-CANCER DRUGS COMPRISING PLATINUM COMPLEXES Field of the invention The present invention relates to novel anti-cancer drugs. According to the invention there are provided platinum complexed anti-tumor immunoglobulins (Igs) which are effective anti-tumor agents which retain their specific anti-body binding capacity. The invention further relates to the preparation of the novel drugs defined above. The binding can be done directly or via dextran-amine moieties. Background of the invention Platinum containing complexes in general andCis-diamino- platinum dihalides (Cis-DDP) in particular are effective anti-tumor agents (Rosenberg et al, Nature (1969),222, 385-6; Leh, J. Pharm.Sci (1976), 65,315. The therapeutic effectivity of such complexes was demonstrated in various experimental animal models (Rosenberg et al, Cancer Res (1970), 30,1799 and others). Furthermore, Cis-DDP is now widely used clinically and is an effective drug against metastatic testicular and ovarian carcinoma. The major drawback of Cis-DDP, as of other anti-cancer agents, is its high degree of toxicity. Other platinum complexes such as condensation products with various amides, mainly the nucleic acid bases uracil and thymine (platinum blues) or platinum complexes with diaminocyclohexanes have been developed. Many such diamino-cis-platinum derivates exhibit anti-tumor activity in vivo and are less toxic. Anti-tumor antibodies have been used as carriers of a number of chemotherapeutic agents in an attempt to increase their specificty towards tumor cells and thereby reduce their general toxicity (Hurwitz et al, Cancer res, (1975), 35, 1175). It was also shown that mixtures of anti-tumor antibodies and drugs were more effective than either of them separately, when applied in vivo in experimental tumor systems. See also U.S. Patents Nos. 4,263,279, and 4,093,607. Summary of the invention According to the present invention there are provided novel platinum complexed anti-tumor immunoglobulins which are useful as drugs for the treatment of certain tumors. The invention further relates to the process for the production of these. The novel pharmaceutically active complexes are prepared by complexing platinum salts with anti-tumor reactive immunoglobulins. When Ig, which has a binding affinity towards certain tumor cells, is complexed with certain platinum salts, highly effective inhibitors of DNA synthesis are obtained. Such complexes are much more effective in inhibiting DNA synthesis than those obtained with normal Ig or with serum albumin. Especially effective prfparations are obtained when platinum salts like KzPtCl4 are complexed with anti-tumor Ig. The complexing can be performed directly or via a dextran-amino moiety. The complexes are prepared by reacting immunoglobulin (Ig) with the desired platinum salt in a suitable medium, such as phosphate buffered saline, and separating the unbound platinum from the product. The toxicity of the novel complexes is lower than that of the conventional cis-diamino-platinum hydrochloride. When equal quantities are administered, the anti-tumor efficacy of the novel complexes is similar to that of the conventional platinum compound. The invention is illustrated with reference to the following illustrative examples, which are to be construed in a nonlimitative manner. Example 1: Ig-Platinum Complex: Tumor Cells - Two types of tumor cells were used. (a) Moloney virus-induced lymphoma, YAC (Klein E., Klein G., J. Nat Cancer Inst, (1964), 32, 547-568) maintained in vivo in A/J male mice, and (b) a 8 cell leukemia, 38c 13 produced in C3H/eB mice by induction with 7,12-dimethylbenz(a)anthracene (Haran-Chera N., Peled A., Nature (1971), 24, 396-398). For the experiments the tumor cells were kept in culture in RPMI-1640 media containing 10% fetal calf serum (FCS), glutamine antibiotics and 15 5M fl-mercaptoethanol in the case of 38c 13 cells (Bergman Y., Haimovich J., Eur. J. Immunol., (1977), 7, 413-417). Immunoglobulins - Anti-VAC was produced in goats by injection of a soluble papain digest of the VAC cellmembrane as described previously (Hurwitz E. et al, Int. J. Cancer, (1978), 21, 747-755). The anti-38c 13 was produced by injecting goats with a 38c 13 cell-surface IgM. In each case the Ig fraction was precipitated from the antisera by ammonium sulfate at 33Z saturation. A mouse anti-YAC IgM was produced from a hybridoma line according to Kohler G., Milstein C., J.Immunol., (1976), 6, 511-519. The IgM was precipitated from mouse ascitic fluid by ammonium sulfate at 45X saturation. The Ig-platinum complex preparation - The platinum-Ig complex was prepared by reacting 10 mg Ig at a concentration of 50 mg/ml phosphate buffered saline (0,15 M Nazi, .01 M phosphate at pH 7,2, PBS) with .3 mg K2PtCl4 (Ventron, Danvers, Mass.) at a concentration of 6 mg/ml in 0,1 M phosphate buffer, pH 6,4 for 2-3 hours at room temperature. The resulting material was applied to a Biogel P-60 column run in 0,1 M phosphate buffer at pH 6,4 for the separation of bound from free platinum (Fig. 1). The amount of complexed platinum was assayed (a) by a combination of ion exchange, resin loaded papers and X-ray spectrography (Campbell W.J. et al, Anal Che. 1966, 38, 987-996) and (b) the unbound platinum was determined spectrophotometrically (Golla Ed et al, Talanta (1972), 20, 199-210), the complexed platinum was obtained from the difference between the total and the unbound. Free Pt was separated from bound by ultrafiltration through conical membranes (Centriflo, Amicon, Holland). EvaLuation of anti-tumor activity - Inhibition of DNA synthesis, by K2PtCl4, Cis-platinum II and by the novel Ig-platinum compLexes was determined by a method similar to the one described previously by Hurwitz et al, Cancer Res., (1975), 35, 1175. The tumor cells in numbers ranging from 5 x 104 - 5 x 105/my were suspended in their suitable growth media (RPMI-1640 containing 10X fetal calf serum, (FCS). The cells were dispensed in 100 l allquots into the wells of microliter plates (Falcon, Microtest II 3040). The platinum compounds were added to the cells in 50 pl amounts. The plates werde incubated for 2-3 hours at 370C in a humidified atmosphere of 5X C02 in air. At that time, 10 t containing 0,3 pCit3H]-methylthymidine (Nuclear Research Center, Beer-sheva, Israel) were added to each well and the plate was incubated for 20-24 hours as above. The reaction was terminated as described in by T.C.A. precipitation, according to Hurwitz et al, ibid. Antibody activity - The antibody activity of the Igplatinum complexes was determined by (a) Complementmediated lysis - Tumor cells, 5 x 105/ml in 50 yl RPMI-1640 10X FCS were mixed with the 50 pl of antibody solutions and incubated for 40 minutes at room temperature, centrifuged and washed. Fresh guinea pig serum, diluted 1:5 was added to cells (100 Ml/tube). After 1 hour of incubation at 370 C the number of dead or damaged cells was counted by Trypan blue staining; (b) Indirect bindung assay - Antibody solutions diluted in PBS (50 ;il) were added to 5 x 10 YAC cells in 100 ful RPMI-1640 for 1 hour at room temperature. After washing twice 125 I-goat anti-mouse (FAB)2 was added and allowed to stand for another hour at room temperature. After two washings the wells were cut and counted in a gamma counter; (c) Direct binding to radiolabelled antibody - The surface IgM of the 38 leukemia was labelled by the incorporation of±3HJleucine. Dilutions of the antibodies were made in normal goat serum and 50 aliquots were mixed with 50 p1 ofz H7IgM 38 (40,000 cpm) (Eshhar Z. et al, J.Immunol., (1979), 122, 2430-2434). After centrifugation the precipitate was dissolved in 1 M NaOH transferred into scintillation fluid and counted. Complexes of platinum were prepared with a number of immunoglobulins such as goat normal IG (:4G-Ig) goat anti YAC Ig, goat anti-38c 13 Ig, mouse anti-YAC monoclonal IgM and human serum albumin. The concentration of the reactants and the incubation time was varied in the different preparations. The method described above was the most efficient as judged by the highes inhibitory activity of C3yj thymidine uptake in vitro. Using Ig concentrations lower than 50 mg/ml resulted in a reduction of platinum complex to the Ig, while increasing the concentration of the platinate salt during the reaction caused precipitation. The suitable length of incubation was from two to three hours since prolonging the reaction time resulted in precipitation. The binding of Pt to diluted antibody solution is possible but requires a much longer incubation period. Between 1-10 moles platinum were bound per one mole Ig in the different preparations. Inhibition of DNA synthesis as measured by i3Hj-methyl- thymidine uptake was used as a criterium of activity of the platinum complexes. As shown in Fig. 2 the platinate salt, K2PtCl4 and the Cis-NH2PtCl2 both similarly inhibited the uptake of [ C3thymidine by YAC celLs in cuLture. The B leukemia cells C38c 13) were inhibited by the platinate salt and the Cis-DDP only at much higher concentrations than the YAC-cells. The inhibition by the Pt-Ig complexes is depicted in Figs. 3 and 4. The degree of inhibition varied somewhat with the different preparations. However, with all the preparations of anti-tumor reactive Ig-Pt complexes - the inhibition was stronger than could be accounted for by the amount of platinum bound to the Ig as compared to both platinum salt and Cis-DDP. In the YAC system, which was sensitive to the inhibition by the platinum salts, the antibody complexed Pt was about 20 times as effective as the platinates. An inhibitory activity was observed also by platinum complexed to non-specific proteins such as normal Ig and human serum albumin, but this inhibition was apparent only at concentrations considerably higher than those of platinum bound to the cell reactive Ig (Fig. 3). In the B leukemia (38) DNA synthesis was inhibited by the platinum salts, K2PtCl4 and Cis-DDP, only at concentrations above 50 ,ug/ml. Platinum complexed to- antibodies (anti-YAC) which were strongly reactive with the tumor cells was effective inhibitors. Antibodies directed against the specific surface IgM of the 38 cells (idiotypic antibodies), although capable of attaching to the cells, were not as efficient carriers as the anti-YAC Ig which was as reactive with these tumor celLs as with the YAC cell towards which it was directed originally. Complement-mediated cytotoxicity by some Pt-anti-tumor Ig preparations has considerably diminished (Fig. 5). While with ome preparation 55X of the original activity was still maintained in another preparation the activity dropped to 20X of the original.The decrease in complement activity may be reLated to the amount of platinum bound to the antibody or to the occupation by platinum of a complement site. In order to test whether platinum complexing affected the antibody binding capacity, the binding of antibodies to the tumor cells was assayed in the YAC system, indirectly, with 125I-goat anti-mouse (Fab')2 as a second antibody. As shown in Fig. 6, identical binding curves were obtained both with the anti-YAC and with the Pt-anti-YAC, thus the binding of the hybridoma antibody IgM anti-YAC was not affected by its compLexing with platinum. In the B Leukemia (38) system the binding of Pt-anti-38 IgM idiotypic antibodies to ±3H2 labelled IgM (Eshhar Z. et al, J.Immunol., (1979), 122, 2430-2434) was not markedly reduced by the attachment of the antibody to platinum (Fig. 7). Thus, in both systems, the antigen binding capacity of the antibody was not modified by the platinum complexing. It is evident that complexes formed between platinum salts and antibodies retain both the antibody activity and the anti-cancer effect of the platinum. The anti-cancer effect was enhanced with Pt-Ig complexes in which the Ig has a high binding affinity towards the tumor cells. The complexes between Ig and Pt were formed simply by. incubating the platinum salt with the antibodies for a few hours at room temperature. The complexes formed were separated from the free platinum salt by gel filtration (Fig. 1). The anti-tumor cell activity of the Pt-Ig complexes often increased after having been stored for some time. This could be the result of a rearrangement of the platinum position during storage which either brought the platinum to a better orientation towards cell surface antigens or obtained more favorable positions on the antibody itself. The antigen binding capacity of the anti-tumor Ig is almost fully retained (Figs. 6 and 7), whereas the complement fixing ability of these antibodies is reduced to about 20-50 percent of the original in different preparations (Fig. 5). The latter can be attributed to the binding of platinum to portions of the Fc, thereby perhaps blocking the complement recognition site in this part of the molecule. Example 2: Platinum-dextran amine-Ig complex. Tumor cells - Three types of tumor cells were used: (a) and (b) as in Example 1 and (c) the metastatic Lewis lung carcinoma (3LL), a spontaneous tumor originated in 1951 in the lung of a C57BL/6 mouse (Sugiura, K., Stock, C.C. Cancer Res. (1955), 15, 38-51), maintained in C57BL/6 male mice, or in culture in RPMI-1640 medium containing 10% horse serum, glutamine and antibiotics. Immunoslobulins - Anti-Yac and anti 38C 13 Ig were produced as in Example 1. Rat anti-3LL Ig's were produced from hybridoma lines. The Ig was precipitated from mouse ascitic fluid by ammonium sulfate at 45X saturation. Platinum-Dex NH2-Ig complex preparation - Dextran (MW 10.000) was oxidized with a 40 fold molar excess of sodium periodate in double distilled water (DDW) for 16 h. (215or dextran in 100ml DDW). The oxidized dextran was then dialyzed against DDW, lyophilized, and reacted with a 130 molar excess of ethylenediamine in DDW at pH 8,6 for 6 hr. The Schiff bases formed between aldehyde groups on the oxidized dextran and the ethylenediamine were reduced with an equimolar amount of sodium cyanoborohydride at pH 7,5 for 3 hr, the product was dialyzed against DDW and lyophilized. The product (Dex-NH2) formed which contained 4-8-NH-CH2-C112-NH2 groups and another 8-12-NH-CHz-CH2-NH- groups per dextran molecule, is capable of binding 15-20 platinum molecules when interacted with K2PtCl4. Dex-NH2, at a molar excess of 20:1 was coupled via its free NH2 groups to Ig using a 300 molar excess of the bifunctional coupling reagent ethyl-3-(3-dimethyl-aminopropyl) carbodiimide hydrochloride (w/s DCC). Ig and DexNH2 in PBS at pH 5 were mixed with w/s DCC for 5 min, and the pH was then elevated to 7,8. The reaction mixture was incubated at 40 for 5 hr. The Dex-NH2-Ig was precipitated twice with 75t ammonium sulfate to remove unbound Dex-NH2, and dialyzed against PBS. The Dex-NH2-Ig contained 2,5-3 molecules of Dex-NH2 per Ig molecule. Platinum-Dex NH2-Ig complexes were prepared by reacting Dex-NH2-Ig (final concentration 10-15 mg/ml 0,4M NaCl in PBS) with a 200 molar excess of K2PtCl4 (final concentration 5-8 mg/ml) for 16 hr at 40 C. No precipitation of Ig occured. The resulting complex was either applied to Biogel P-60 column as described in example 1 or dialysed against PBS, to remove unbound K2PtCl4. The amount of complexed platinum was assayed (a) by an indirect method i.e., measuring of unbound platinum as described in Example 1 or (b) by direct evaluation using the atomic absorbtion. Evaluation of anti-tumor activity - Inhibition of DNA synthesis in tumor cells by novel platinum -Dex-NH2-Ig complexes was performed as in Example 1, except that the plates were incubated for 24 or 48 hrs. and 3 hrs before termination of culture, the plates were pulsed with either 0,5 tjc3H methyl-thymidine or with 1 pc 3H7 leucine, in order to assess inhibition of protein synthesis. The reaction was terminated using a Titerteck Cell Harvester. Antibody activity - The antibody activity of the platinum Dex-NH2-Ig complexes was determined by (a) Fluorescence analyzer cell sorter - tumor cells, 2 x 106 in 50 pl PBS containing 0,5X bovine serum albumin and 0,05X sodium azide were incubated at OOC with 10-20 ug of antibody solutions in 50 ul for 30 min, washed 3 times and incubated for additional 30 min with fluorescent labeled antibodies directed against the first antibody. The cells were then washed, fixed with paraformaldehyde, and analysed. (b). Radio-immunoassay-tumor cells were incubated with antibody solutions as is (a), washed and incubated again with 1251 second antibody solutions. After washing, the cells were counted in a gamma counter. Complexes of platinum were prepared with free Dex-NH2, or with Dex-NH2 bound to normal goat Ig (NIg), goat anti YAC Ig, goat anti 38C 13 Ig and anti-3LL Ig from hybridoma lines monoclonal antibodies), respectively. The conditions described above for the preparation of Pt-Dex-NH-Ig were optimal as judged by the highest extent of Dex-NH2 conjugation and platinum complexing while retaining most of the antibody activity. The amount of platinum complexed to the Dex-NH2-Ig as determined by either method described above was comparable and was found to range between 40-60 moles platinum per mole Ig. The pharmacological activity of the platinum conjugates was evaluated by inhibition of DNA synthesis, as measured by t3IJ methyl-thymidine incorporation. Figure 8 demonstrates the inhibition of DNA synthesis in YAC lymphoma cells. Pt-Dex-NH2anti-YAC Ig (Ig fraction of antiserum prepared against a soluble papain digest of YAC cell membrane) was a better inhibitor than K2PtCl4 (50Z inhibition at 4,5 and 12 Mg/ml respectively). All concentration values were calculated in platinum equivalents. As shown in Fig. 9, Pt-Dex-NHz and Pt-Dex-NH2-NIg were both poor inhibitors. A more significant effect was observed in the system of the B leukemia (38C 13) cells (Fig. 9): Higher concentrations of K2PtCl4 were required for DNA inhibition (50X at 25-30 tug/ml). However, when complexed to Dex-NH2 anti-38C Ig (idiotypic antibodies directed against the specific surface IgM of 38 cells), the platinum was a very effective inhibitor, leading to 50X inhibition at 0,7 Ftg/ml after 48 hrs of incubation (inhibition after 24 hrs was only slightly lower, with 50X inhibition at 1 )Ig/ml). Pt-Dex-NH2-NIg was a much weaker inhibitor (50X at 20 yg/ml) and Pt-Dex-NH2 was a poor inhibitor. Platinum complexes with Dex-NH2 derivatives of monoclonal antibodies directed against 3LL tumor cells were more effective than either free K2PtCl4 or the Pt complexes with Dec-NH2-NIg or Dex-NH2 (50X inhibition at 8, 33, 27 and 46 IJg/ml, re-spectively) (Fig. 10). The tumor cell binding capacity of the Pt-Dex-NH2-Ig specific complexes was mostly retained as judged by the fluorescent cell sorter analyser experiments and by radioimmunoassays. Since both assays are indirect, at least some loss of antibody activity might be attributed not necessarily to loss of combining site function but also to decrease of secondary antibody binding of the modified first antibody. The mechanism of the platinum anti-tumor activity is not known. In vitro it was shown to interact with DNA. Several in vivo studies suggested an involvement of the immune system in promoting platinum action. Immunodepressing compounds such as hydrocortisone were shown to decrease platinum potency, while immunostimulants such as zymosan were shown to increase it. Preliminary experiments in vivo indicate that the novel complexes have a lower toxicity than that of the conventional cis-diaminoplatinum dihalides. Furthermore, the dosages required for an equal effect are lower than those of the conventional cis-DDp or of platinum complexes with various amides, nucleic acid bases and the like. The platinum-antibody conjugates of the present invention are characterized by a therapeutic activity at least equal to that of the conventionally used ci s-platinum compositions. The general toxicity of the conjugates of the present invention is lower, and thus for equal dosages, a lower overall toxicity will result. This makes possible the administration of larger dosages, if required,with a toxicity not exceeding that of the dosages used nowadays. Due to the specificity of the novel compositions, i.e. their recognition of the tumor cells due to the specific conjugated antibodies, the result is a "targeting" of the drug to the site of the tumor, reducing general systemic toxicity and increasing the local effectivity of the drug which appears in concentrated form at the very site where it is needed, i.e. at the site of the tumor where the ci s-platinum exerts its full activity. In the Figures, Fig. 1 illustrates the fractionation of platinum-goat anti-YAC, Ig for the separation from unbound platinum. After complexing Pt with Ig the materiaL was appLied to a column of Biogel P-60 (Bio-rad 16 x 2 cm) run in 0,1 M phosphate buffer at pH 6, 4 Fractions of 1 ml were collected. The Ig-Pt was determined by absorbance at 280. Aliquots of the unbound Pt were analyzed spectrophotometrically; Fig. 2 illustrates the inhibition of DNA synthesis by platinum salts. The inhibition of DNA synthesis by the pLatinates was measured by their effect on the incorporation of L-3H0methylthymidine. YAC cells (10 /well) or 38c 13 cells (4 x 10 well) were incubated with platinum salts for 2-3 hours at 370 after whichC3llJmethylthymidine was added and incubation was continued overnight. The reaction was termirated by T.C.A. precipitation; Fig. 3 illustrates the inhibition of 3HJthymidine incorporation of YAC cells, by various Pt-protein and Ig complexes. Pt-HSA (x), Pt-NGIg (.) Pt-anti-38 Ig, prep. 1 (V---), Pt-anti-38 Ig, prep. 2 (V), Pt-anti-YAC, (goat Ig) ( ), Pt-anti-YAC (hybridoma IgM) (o). The platinum content of these preparations is about 10-12 M/M except Pt anti-38 prep. 2 which contains only about 2 M/M; Fig. 4 illustrates the inhibition of C3HJthymidine incorporation of 38 leukemia cells, by various Pt-Ig preparations. Pt-anti-YAC Ig prep. 1 ( ), Pt-anti-YAC Ig, prep. 2 (o), Pt-anti-38 Ig (*), Pt-NGIg (V). The platinum content of these preparations is about 10-20 M/M; Fig. 5 illustrates antibody activity of Pt-anti-YAC complexes measured by complement mediated cytotoxicity. The complement mediated lysis of YAC cells was measured by incubating YAC cells (5 x 105) with dilutions of anti-YAC, goat Ig or Pt-anti-YAC complexes. Anti-YAC Ig, prep. 1 (x), anti-YAC Ig, prep. 2 (e). Pt-anti-YAC, prep. 1 (o) Pt-anti- YAC, prep. 2 (.); Fig. 6 illustrates the antibody binding activity of Pt-anti-YAC, IgM complexes. The antibody binding activity of a hybridoma anti-YAC IgM to YAC formaline-fixed cells (105/well) was measured after its complexing with platinum. The binding activity was measured indirectly with 1251-goat anti-mouse (Fab')2. Mouse anti-YAC, IfM EMI13.1 Pt-mouse anti-YAC (x-x); and Fig. 7 illustrates the antibody binding activity of Pt-anti38 complexes. The antigen binding of Pt complexed anti-38 goat Ig was measured by a drect binding assay using the t3 Hj-labelled antigen surface IgM of the 38 leukemia cells. Goat anti-38 Ig (V), Pt-anti-38 Ig, prep. 1 (t ), Pt-anti38 Ig, prep. 2 (ss); Fig. 8 illustrates the inhibition of [ H] thymidine incorporation into DNA of YAC cells (5 x 104cells/well) by Pt-Dex-NH2-anti YAC Ig (o), K2PtCL4 te), Pt-Dex-NH2 (x) and Pt-Dex-NH2-NIg (A). Cells were incubated with the platinum compounds (or with PBS for control) for 21 hrs at 37 C after which r H] methylthymidine was added and incubated proceeded for 3 more hours; Fig. 9 illustrates the inhibition of CHJ thymidine incorporation of 38 leukemia cells (figure signs as in Fig. 1 . Cells (104 ceLlsiwell) were incubated with the platinum compounds for 45 hrs (as above) followed by a 3 hrs pulse of [3H] methylthymidine; Fig. 10 illustrates the inhibition of ±±3HJ thymidine incorporation of 3LL cells (5 x 104 cellslwelL) by Pt-Dex NH2 anti 3LL /hybridoma IgG) (o) K2PtCl4 (S), Pt-Dex-NH2 (x) and Pt-Dex-NHz-NIg (A). Cells were incubated with the platinum compounds for 45 hrs followed by a 3 hrs pulse of methylthymidine.

Claims: Claims 1. An anti-tumor agent wherein platinum is complexed directly or via dextran-amine moiety to an anti-tumor immuno globulin. 2. An anti-tumor agent according to Claim 1, being the product of complexing an anti-tumor immunoglobulin with a platinum salt. 3. An anti-tumor agent according to Claim 2, wherein the platinum salt is K2PtCl4. 4. An anti-tumor agent according to Claim 1, being the product of complexing of an immunoglobulin coupled to a dextran-amine with a platinum salt. 5. An anti-tumor agent according to Claim 1, wherein the immunoglobulin is specific for ovarian or testicular carcinoma or for renal adenocarcinoma. 6. An anti-tumor agent according to Claim 1 in the form of an injectable liquid. 7. A process for preparing an anti-tumor immunoglobulin complex with platinum which comprises reacting a tumor specific immunoglobulin with K2PtCL4 in a reaction medium and removing the unreacted platinum. 8. A process for preparing an anti-tumor agent wherein platinum is complexed via a dextran-amine to an anti tumor immunoglobulin, which comprises oxidizing dextran, reacting same with ethylenediamine, reducing same, coupling same to a suitable immunoglobulin and reacting the thus formed product with a platinum salt.

Inventors: ARNON, RUTH, HURWITZ, ESTHER, KASHI, RENA, SCHECHTER, BILHA, SELA, MICHAEL, WILCHEK, MEIR
Applicants: YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD.
Application year: 1983
Main classification: A61K39
IPC codes: A61K47, A61K39